New Flu Strain Spreading in Europe: Vaccination Recommended

“`html

New Flu variant ‘Subclade K’ dominates Early 2026 Season, Vaccination Remains Key Defence

Despite a new influenza strain circulating globally, health officials are urging the public to get vaccinated, emphasizing that immunization remains the most effective way to mitigate severe illness adn hospitalization. The 2025-2026 flu season is beginning with the rapid spread of a novel variant of the influenza virus, prompting concerns about potential strain on healthcare systems.

Emerging Threat: A/H3N2 ‘Subclade K’

The dominant strain currently circulating is a new variant of the A/H3N2 flu virus, identified as subclade K. this variant has already fueled a surge in cases in Britain,Canada,and Japan,and is anticipated to increase illness rates in the United States. Researchers note that the current flu vaccine is not a perfect match for this evolving strain.

According to a study by a Canadian team published in the journal of the Association of Medical Microbiology and Infectious Disease Canada, A/H3N2 viruses have undergone significant evolution following a period of relative stability after the COVID-19 pandemic. This evolution continued throughout the Southern hemisphere’s influenza season, with subclade K predicted to be the primary circulating strain in the Northern Hemisphere this winter.

Did you know?– The flu vaccine is updated annually to address circulating strains, but viral evolution can sometimes outpace these adjustments, leading to reduced effectiveness.

Severity Concerns and Vaccine Effectiveness

Experts warn that the A/H3N2 virus tends to cause more severe illness, particularly among vulnerable populations. “The A/H3N2 virus tends to cause more severe forms compared to A/H1N1, especially in the elderly,” cautioned a specialist in infectious diseases at the University of Glasgow. The elderly, pregnant women, and individuals with chronic diseases remain at the highest risk of developing severe complications from the flu.

An analysis released by the British Government on November 11th, currently undergoing scientific review, suggests the existing vaccine offers an estimated 70% to 75% effectiveness in preventing hospitalizations among children aged 2 to 17. However, effectiveness drops to 30% to 40% in adults. Despite this reduced efficacy against the dominant strain, health authorities maintain that these numbers are within typical ranges for a flu season.

Pro tip:– Even with reduced vaccine effectiveness, getting vaccinated can lessen symptom severity and the risk of complications, like pneumonia.

Regional Variations and Current Circulation

While the new variant is gaining traction globally, the situation varies regionally. In Romania, data indicates a lower level of viral circulation compared to pre-pandemic seasons. As of the week of November 3-9, 2025, the National Center for Surveillance and Control of Communicable Diseases reported 65,081 cases of acute respiratory infections – a 4.5% decrease from the previous week and a 20.3% decrease compared to the same week last season.

Though, clinical flu cases have increased compared to the same week in the previous season, rising from 208 to 302 cases nationally. A total of 18 laboratory-confirmed influenza cases have been reported since the start of the season, with a diverse range of subtypes circulating, including non-subtyped influenza A, A(H3), A(H1), and influenza B.

Reader question:– Is it still worth getting a flu shot if the vaccine isn’t a perfect match? Yes. Vaccination provides some protection and reduces the risk of severe outcomes.

Vaccination Efforts Underway

Despite the challenges posed by the new variant, vaccination efforts are progressing.Through November 9, 2025, a total of 963,452 influenza vaccine doses had been administered, with the vast majority – 946,23